Using guideline-directed medical therapies to improve kidney and cardiovascular outcomes in patients with chronic kidney disease.
Publication Title
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Document Type
Article
Publication Date
4-8-2025
Keywords
washington; spokane; pmrc
Abstract
PURPOSE: An estimated 37 million people currently live with chronic kidney disease in the US, which places them at increased risk for kidney disease progression, cardiovascular disease, and mortality. This review discusses current standard-of-care management of patients with chronic kidney disease, identifies key gaps in care, and briefly highlights how pharmacists can address gaps in care as members of the multidisciplinary care team.
SUMMARY: Recent advances in guideline-directed medical therapies for patients with chronic kidney disease, including agents from the sodium-glucose cotransporter, glucagon-like peptide-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist classes, can dramatically improve cardiovascular-kidney-metabolic care and outcomes. Unfortunately, gaps in screening, diagnosis, and implementation of recommended therapies persist. Team-based models of care-inclusive of the person with chronic kidney disease-have the potential to significantly improve care and outcomes for people with chronic kidney disease by addressing current gaps in care.
CONCLUSION: As members of the multidisciplinary care team, pharmacists can play a critical role in addressing current gaps in care, including optimized use of guideline-directed medical therapies, in patients with chronic kidney disease.
Area of Special Interest
Kidney & Diabetes
Area of Special Interest
Cardiovascular (Heart)
Specialty/Research Institute
Cardiology
Specialty/Research Institute
Endocrinology
Specialty/Research Institute
Nephrology
DOI
10.1093/ajhp/zxaf045
